Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.25.1 (
proteasome
)
28,817
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The ubiquitin-
proteasome
pathway degrades ubiquitinated proteins to remove damaged or misfolded protein and thus plays an important role in the maintenance of many important cellular processes. Because the pathway is also crucial for tumor cell growth and survival,
proteasome
inhibition by specific inhibitors exhibits potent antitumor effects in many cancer cells. xCT, a subunit of the cystine antiporter system xc (-), plays an important role in cellular cysteine and glutathione homeostasis. Several recent reports have revealed that xCT is involved in cancer cell survival; however, it was unknown whether xCT affects the cytotoxic effects of
proteasome
inhibitors. In this study, we found that two stress-inducible transcription factors, Nrf2 and ATF4, were upregulated by
proteasome
inhibition and cooperatively enhance human xCT gene expression upon
proteasome
inhibition. In addition, we demonstrated that the knockdown of xCT by small interfering RNA (siRNA) or pharmacological inhibition of xCT by sulfasalazine (SASP) or
(S)-4-carboxyphenylglycine
(CPG) significantly increased the sensitivity of T24 cells to
proteasome
inhibition. These results suggest that the simultaneous inhibition of both the
proteasome
and xCT could have therapeutic benefits in the treatment of bladder tumors.
...
PMID:Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition. 2604 38